KEYNOTE-966: Three-Year Follow-Up for Advanced Biliary Tract Cancer

Richard Finn, MD, of University of California, Los Angeles, highlights 3-year follow-up data from KEYNOTE-966.
The study assessed pembrolizumab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer.